At AstraZeneca, an early adopter of AI and data ... way we discover and design medicines," says Weatherall. “The use is no longer an 'add on' or 'nice to have,' but an essential and integrated ...

Thought LeaderMina MakarSenior Vice President, Global CVRMAstraZeneca NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart ...

Copies of AstraZeneca Plc’s Calquence tablets proposed by MSN Laboratories Pvt. Ltd. infringe two patents for the blood-cancer treatment, according to a federal lawsuit filed six months after MSN ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review in the U.S. for the treatment of adult patients with ...

AstraZeneca still trades at a premium valuation ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

Bullish option flow detected in AstraZeneca (AZN) with 6,710 calls trading, 1.6x expected, and implied vol increasing almost 4 points to 24.02%. Mar-25 72.5 calls and 1/10 weekly 67 calls are the ...

Background Clozapine is currently the only antipsychotic drug approved by the Food and Drug Administration (FDA) of the United States for treatment-resistant schizophrenia.